22Z Stock Overview
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Zealand Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 107.00 |
| 52 Week High | DKK 130.40 |
| 52 Week Low | DKK 46.14 |
| Beta | 0.53 |
| 1 Month Change | 19.42% |
| 3 Month Change | -12.30% |
| 1 Year Change | 117.66% |
| 3 Year Change | 445.64% |
| 5 Year Change | 253.60% |
| Change since IPO | 1,063.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 22Z | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.4% | -1.2% | -1.4% |
| 1Y | 117.7% | -13.2% | 8.0% |
Return vs Industry: 22Z exceeded the German Biotechs industry which returned -13.2% over the past year.
Return vs Market: 22Z exceeded the German Market which returned 8% over the past year.
Price Volatility
| 22Z volatility | |
|---|---|
| 22Z Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 22Z's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 22Z's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 298 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Zealand Pharma A/S Fundamentals Summary
| 22Z fundamental statistics | |
|---|---|
| Market cap | €7.60b |
| Earnings (TTM) | -€141.13m |
| Revenue (TTM) | €10.31m |
737.5x
P/S Ratio-53.9x
P/E RatioIs 22Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 22Z income statement (TTM) | |
|---|---|
| Revenue | DKK 76.87m |
| Cost of Revenue | DKK 704.13m |
| Gross Profit | -DKK 627.26m |
| Other Expenses | DKK 425.28m |
| Earnings | -DKK 1.05b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 20, 2025
| Earnings per share (EPS) | -14.90 |
| Gross Margin | -816.00% |
| Net Profit Margin | -1,369.25% |
| Debt/Equity Ratio | 3.2% |
How did 22Z perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 10:07 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zealand Pharma A/S is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kerry Holford | Berenberg |
| Laura Hindley | Berenberg |
| Charlie Haywood | BofA Global Research |